FCGR2A and neoplasm: The capacity of elotuzumab to stimulate macrophage-mediated anti-myeloma phagocytic activity by activating the FcγR is shown by Kurdi et al. According to reports, elotuzumab also boosts macrophage activation in addition to enhancing macrophage concentration at the tumor location [161].